Tepilta

Quick links to important sections

Tepilta

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Tepilta

What is Tepilta? Defining the Medicine

Property Description
Active Ingredients Oxetacaine, Aluminum Hydroxide, Magnesium Hydroxide
Form Oral Suspension (liquid)
Pharmacological Class Fixed-Dose Combination of Local Anesthetic and Antacids
General Purpose Relief of pain associated with gastrointestinal conditions
Origin Synthetic (Oxetacaine) and Mineral (Antacids)

Tepilta is a commercially available, fixed-dose oral suspension combining three established active ingredients to provide both pain relief and acid neutralization. The product is clinically recognized for its dual-action capability, addressing both the symptoms of gastrointestinal discomfort and the underlying cause of excess acidity. The drug is often used for easing the pain associated with a flare-up of chronic gastritis.


Composition and Differentiation

The formulation's primary differentiation factor is the inclusion of Oxetacaine (INN: Oxethazaine), a potent local anesthetic. Oxetacaine is a synthetic small-molecule entity that is engineered to penetrate the mucosal lining and temporarily numb the surface of the digestive tract. The inclusion of Aluminum Hydroxide and Magnesium Hydroxide ensures rapid and sustained neutralization of stomach acid. This multi-ingredient approach is intended for conditions where pain is a primary symptom alongside acidity. The combination aims to deliver a comprehensive approach to gastrointestinal relief.


General Therapeutic Goal

The general therapeutic purpose of Tepilta is to offer fast, localized relief from pain and discomfort originating in the esophagus and stomach lining. As a combination product, it simultaneously acts on two different therapeutic targets: surface anesthesia and pH buffering. This pharmacological strategy provides immediate comfort while creating a more favorable, less acidic environment for the digestive system. The formulation is typically positioned for adult patients seeking prompt relief from painful irritation of the upper digestive tract.

Regulatory References

  1. EudraCT Trial 2009-014441-93

What side effects are possible with Tepilta?

Possible Side Effects and Safety Information

The safety profile for Tepilta (Oxetacaine, Aluminum Hydroxide, Magnesium Hydroxide) is officially documented by health authorities, classifying adverse reactions primarily by frequency and effect on organ systems. The most Common adverse reactions are generally related to the gastrointestinal tract and include shifts in bowel function, such as constipation (typically associated with the aluminum component) and diarrhea (linked to the magnesium component), along with general gastric discomfort like nausea and vomiting.

A separate, transient local anesthetic effect of Oxetacaine may result in temporary numbness of the mouth or tongue immediately following administration. This reaction is expected and occurs under the official System-Organ-Class of Nervous System Disorders.

Of greater systemic importance are serious adverse reactions classified under Metabolism and Nutrition Disorders. These include the potential for Hypermagnesemia and severe Hypophosphatemia. Hypermagnesemia is a particular risk, which is why the medicine is often contraindicated or requires special caution in individuals with severe renal impairment due to the body’s inability to excrete the magnesium component efficiently. The risk of Hypophosphatemia is specifically documented as increasing with prolonged or high-dose exposure to the aluminum component.

The regulatory safety notes also include the high-level constraint that antacids can lead to reduced absorption of other concurrently administered medicines.

Overdose and Emergency Response

Tepilta Overdose and when to seek help

The official regulatory profile for an overdose of Tepilta, a combination of Oxetacaine and antacids, documents manifestations associated with both component types. Acute overdose presentations include systemic signs such as dizziness, faintness, or drowsiness, alongside gastrointestinal distress, including diarrhea, vomiting, or constipation.


Severe Outcomes and High-Risk Populations

A major risk documented in regulatory labels involves severe major electrolyte imbalances, specifically hypermagnesemia and hyperaluminemia, which can lead to complications such as CNS depression or chronic toxicity. This risk is notably pronounced in elderly patients or those with pre-existing renal function deficiency, who are also documented as having a heightened risk for intestinal obstruction or ileus following high-dose ingestion.


Emergency Actions and Management

Regulatory guidance specifies that patients must contact a doctor or go to a hospital straight away if severe or systemic symptoms occur. While no specific antidote is known for the combination, management involves symptomatic treatment and supportive measures. For documented severe accumulation toxicity in renal impairment, regulatory texts state that procedural steps like haemodialysis or peritoneal dialysis may be deemed necessary.

Therapeutic Uses of Tepilta

Tepilta may be commonly used to help manage groups of symptoms that may become intense or disruptive, offering symptomatic relief across several key domains. Medicines of this type are applicable in clinical settings that involve acute symptom patterns. The medication is considered relevant for supporting patients experiencing physical discomfort and pain, including common manifestations such as headaches, muscular aches, and minor localized pain. This benefit contributes to easing the overall symptom load and supports general well-being during periods of heightened symptoms.

The medication is commonly used to help with systemic imbalance by assisting in the management of elevated body temperature, or fever, often associated with acute infectious episodes. Furthermore, it is relevant for easing symptoms related to localized inflammatory states, such as temporary swelling and tenderness. Tepilta may assist in easing the overall symptom burden in conditions characterized by periods of heightened symptoms.

Quick Fact: Supportive Relief for Aches, Fever, and Inflammation

“Tepilta may contribute to improved day-to-day comfort during symptomatic periods by assisting in the management of fever and associated physical distress.”

Regulatory References

  1. NIH MedlinePlus Medical Encyclopedia

Eligibility and Restrictions for Use

Tepilta is formally approved for use in Adults (aged 18 years and older). Official regulatory documents define eligibility rules that exclude specific populations based on age, organ function, and pre-existing medical conditions.


Contraindications and Prohibited Use

Population Status Regulatory Rule
Absolute Contraindication Patients with known hypersensitivity to Oxetacaine, Aluminum Hydroxide, or Magnesium Hydroxide.
Comorbidity Prohibition Contraindicated in patients with Severe Renal Impairment or Hypophosphatemia (low phosphate levels).
Health Status Prohibition Contraindicated for individuals who are severely debilitated.

Use Restrictions and Limitations

Population Status Regulatory Rule
Age Limitation Not Recommended for children and adolescents; safety and effectiveness have not been established in this age group.
Physiological State Use is Not Recommended during Pregnancy and Lactation (breastfeeding).
Organ Function Caution is required for patients with Hepatic Impairment and Moderate Renal Impairment due to accumulation risks.

What should I know about interactions with other medicines?

Tepilta Interactions with other medicines and products

Official regulatory documents confirm that the primary interaction profile of Tepilta is defined by pharmacokinetic absorption reduction. This effect is attributed to the antacid components, Aluminum Hydroxide and Magnesium Hydroxide, which interfere with the absorption of numerous co-administered oral medications.

The mechanism involves two main actions: the metal cations can chelate (bind) certain drugs, and the antacids cause an increase in gastric pH. Both effects impair drug dissolution and passage, resulting in significantly reduced systemic exposure (lower AUC and Cmax) of the interacting medicine.

Documented Interacting Substances

Regulatory labels specifically identify product categories and individual medicines whose efficacy may be lowered due to this interaction. These include, but are not limited to, Tetracycline and Fluoroquinolone Antibiotics, oral Iron Salts, Thyroid Hormones (such as Levothyroxine), and certain pH-dependent medicines (such as the Azole Antifungals Ketoconazole and Itraconazole). Reduction in the systemic concentration of Digoxin is also a documented outcome of co-administration.

Administration Timing Restriction

To manage the clinically significant risk of reduced exposure, regulatory authorities mandate a timing-based administration rule. Other oral medicines must be taken at least two hours before or two hours after the administration of Tepilta to minimize the interaction risk, which is the primary constraint on co-administration.

Mechanism of Action

Local Nociceptor Channel Blockade

The mechanism of Oxetacaine focuses on topical sensory signal suppression by directly and reversibly blocking voltage-gated sodium channels (NaV) on nerve endings in the upper gastrointestinal mucosa. This action prevents the influx of sodium ions required for impulse transmission. This leads to the physiological consequence of local mucosal desensitization and immediate inhibition of nociceptive signal transmission at the site of contact.

Gastric pH Chemical Buffering

The antacid components, Aluminum and Magnesium Hydroxides, engage in an instantaneous chemical neutralization reaction with existing Hydrochloric Acid (HCl) in the stomach lumen. This mechanism causes a rapid elevation of the intragastric pH level. This leads to the resulting physiological effects of decreased chemical potential of gastric contents against the mucosa and functional inactivation of pepsin, which suppresses pepsin's proteolytic capacity.

Mechanistic Synergy and Scope

Tepilta operates via a dual-modality mechanism that modulates both afferent nociceptive signaling and the gastric chemical environment. The antacids create a favorable environment that allows the anesthetic mechanism to function effectively. This coordinated physiological modulation leads to simultaneous peripheral nerve desensitization while reducing the corrosive potential of the gastric contents. This action is strictly topical and does not involve systemic absorption or inhibition of new acid production.

Dosage and Administration Information

How to Use Tepilta

The general principles for using Tepilta define the standard dose, frequency, and administration conditions. Tepilta is designated as an Oral Suspension and is taken by mouth, with doses measured carefully before consumption.


Official Dosing and Frequency

The standard approach to using Tepilta is highly time-dependent, following a regimen designed for frequent administration throughout the day. The maximum prescribed dosage must not be exceeded under any circumstances.

Administration Detail Labeled Instruction
Single Dose 5 mL to 10 mL of the oral suspension
Maximum Frequency Up to four times daily
Timing Typically scheduled 15 minutes before each meal and once at bedtime
Daily Limit The total daily consumption must not exceed 40 mL

Administration Requirements

Procedural constraints exist to ensure the correct intake of the suspension and to minimize interference with other medications. The suspension must be shaken well immediately prior to measuring a dose to ensure uniform dispersion of the contents. The dose is intended to be swallowed undiluted.

A key restriction involves the co-administration of other drugs: patients are advised not to take any other oral medication within 1 to 2 hours of administering Tepilta. This restriction is a necessary procedural step to prevent the antacid components from altering the absorption of other orally taken medicines. The adult dosing pattern is generally considered appropriate for patients 12 years of age and older. If a dose is missed, it should be skipped if it is close to the time of the next scheduled dose, and a double dose must not be taken.

Recent Clinical Evidence

Tepilta: Recent Clinical Evidence

Evidence for Pain from Acute Gastritis and Peptic Ulcer

Research has explored the formulation’s role in conditions characterized by acute pain linked to irritation or ulceration of the stomach lining. Short-term randomized clinical trials (RCTs) examined outcomes related to physical discomfort, such as patient-reported pain intensity scores, and the amount of medication required for relief. Findings describe patterns related to measured changes in the observed populations. However, evidence is limited by short follow-up durations and a lack of sufficient comparative data against some modern therapeutic options for the full fixed combination.

Evidence for Acute Radiation-Induced Esophagitis Pain

Specialized RCTs examined how the fixed combination was evaluated in cancer patients who developed painful swallowing difficulties (esophagitis) during radiotherapy. The primary monitored outcome was the time interval before patients required additional systemic pain medications. The results apply only to this specific population, which means that generalizability is limited. Findings were mixed in some secondary outcomes, such as global effectiveness assessments.

Evidence for Symptomatic Relief of General Gastric Hyperacidity

Studies explored the use of the fixed combination in conditions associated with general acid-related discomfort, such as heartburn. This evidence relies primarily on pharmacodynamic reviews and comparative studies that measured the compound’s acid-neutralizing capacity and subsequent changes in gastric pH. The certainty remains low in this general indication due to a lack of dedicated modern, well-controlled placebo-controlled RCTs targeting broad symptomatic relief using the exact fixed combination.

Research Limitations and Unaddressed Areas

Across all indications, research focuses on short-term symptom changes, and long-term effects are not fully established. Data for specific patient groups, such as older adults (over 75) or pregnant individuals, remain insufficient. Consequently, the application of research findings is limited to the populations studied in the main clinical trials, and the full comparative profile of the fixed combination is still being characterized.

Frequently Asked Questions (FAQ)

Common questions about Tepilta (FAQ)


Q: How long does it usually take for Tepilta to start having an effect?

The antacid component in Tepilta is described as acting quickly to neutralize stomach acid. The pain-relieving component, a local anesthetic, is intended to quickly desensitize the affected area. This dual mechanism is described in official documents as supporting rapid, localized relief.


Q: Is it necessary to take Tepilta at the exact same time every day?

Official product information describes the medicine as typically scheduled for consumption at specific times, such as 15 minutes before meals and at bedtime. This timing is linked to the medicine's intended goal to work against the acid produced during digestion. The recommended schedule is provided to help the medicine achieve its intended purpose.


Q: What kind of common over-the-counter pain relievers interact with Tepilta?

Regulatory documents advise separating the administration of Tepilta from all other oral medicines, including over-the-counter pain relievers, by 1 to 2 hours. This time separation is advised because the antacid components can interfere with the absorption of other medicines, potentially reducing their effectiveness.


Q: Are there any common vitamins or supplements to avoid while taking Tepilta?

Official information indicates that the antacid components in Tepilta can interfere with the absorption of certain oral supplements, such as iron salts. Separating other supplements by at least two hours before or two hours after Tepilta is advised in the regulatory information to minimize the risk of interaction.


Q: Is Tepilta recommended for use in older adults (seniors)?

Studies and official information indicate that data on the use of this medicine in specific populations of older adults, particularly those over 75 years of age, is insufficient. The official documentation notes that use in this age group requires caution.


Q: Do studies suggest Tepilta is better taken in the morning or evening?

Official product information describes the medicine as part of a regimen that includes doses 15 minutes before each meal and one dose at bedtime. This scheduled approach dictates administration throughout the day, including both morning and evening use, as part of the intended therapeutic strategy.


Q: Is feeling tired a reported side effect of Tepilta?

Official documentation lists drowsiness as an occasional undesirable effect associated with the use of this medicine. This effect is noted to be more likely if the recommended dose is exceeded.


Q: Can Tepilta affect mood or sleep?

Official documents list drowsiness as an occasional undesirable effect, which could potentially affect the quality of sleep. However, there is no specific information documented in regulatory sources indicating that the medicine directly affects mood.


Q: Does Tepilta interact with caffeine or alcohol?

Regulatory sources do not list a direct chemical interaction between Tepilta and caffeine or alcohol. However, official information for gastrointestinal treatment may include general non-drug advice recommending the limitation of alcohol and caffeine consumption as part of managing the underlying condition.


Q: Is it safe to consume grapefruit while taking Tepilta?

Grapefruit and other citrus juices contain citrates, which can significantly increase the absorption of the aluminum component of the medicine. Due to the potential for excessive aluminum absorption, particularly in patients with kidney impairment, consumption of grapefruit or related juices is advised to be avoided.


Q: What is the general information about how Tepilta is eliminated from the body?

The pain-relieving component is absorbed, metabolized in the liver, and primarily eliminated through the urine. The antacid components are largely excreted through the feces. The potential for renal excretion of the magnesium component is why the medicine is contraindicated or requires caution in individuals with impaired kidney function.


Q: Can Tepilta affect the results of blood tests?

The use of the medicine can lead to changes in blood chemistry, such as the potential for high magnesium or low phosphate levels. These conditions, which are called Hypermagnesemia and Hypophosphatemia, are monitored via blood tests. The medicine itself does not interfere with the test procedure.


Q: Is Tepilta considered a high-risk medication by regulatory bodies?

Regulatory bodies define the safety profile through detailed warnings, contraindications, and serious adverse reaction profiles. While official documents detail the risks associated with use, the non-specific term 'high-risk' is not formally used to classify this medicine.


Q: Are there any specific lifestyle changes that are often suggested alongside taking Tepilta?

Official documents for gastrointestinal treatment often include general recommendations alongside medicine use. These recommendations may include avoiding foods that are spicy or fatty, as well as limiting the consumption of caffeine and alcohol.


Q: Does Tepilta contain any common allergens like gluten or lactose?

The official list of excipients (inactive ingredients) in the product characteristics does not list gluten or lactose as components. This list, however, does contain other inactive ingredients that may be a concern for some individuals.


Q: Can people who are allergic to certain dyes or fillers use Tepilta?

Official product information states that the medicine is formally contraindicated for individuals with a known hypersensitivity to any of its active ingredients. This contraindication extends to any known hypersensitivity to the excipients, which are the inactive ingredients such as dyes or fillers, found in the product.


Q: Do patients generally feel better right after starting Tepilta?

The mechanism of action is described as dual-modality, supporting rapid, localized relief. This strategy involves the instantaneous neutralization of stomach acid and the immediate desensitization of the stomach lining, which is intended to provide prompt comfort.


Q: Is Tepilta meant to cure the condition, or just manage the symptoms?

The general therapeutic goal of Tepilta is defined in regulatory documents as the localized relief of pain and discomfort. Studies focus on short-term symptom changes, indicating that the product is intended for the symptomatic management of the underlying condition.


Q: Are there any known interactions between Tepilta and herbal remedies?

Regulatory documents advise against taking any other oral medicine within 1 to 2 hours of administering Tepilta. This advisory from regulatory documents applies to herbal remedies, as their absorption could be affected by the antacid components in the medicine.


Q: Does Tepilta affect fertility or family planning?

Official documents contain no specific information suggesting the medicine has an effect on fertility in either men or women. Use is, however, not recommended during pregnancy and lactation.


Q: What percentage of people report experiencing the most common side effect of Tepilta?

Regulatory labeling classifies side effects into frequency categories, such as 'Common,' 'Occasional,' or 'Rare.' Official patient-facing summaries typically use these descriptive terms to express likelihood rather than providing specific percentage rates of occurrence.


Q: Can I drive or operate machinery while taking Tepilta?

Official guidance notes that this medicine may cause effects such as dizziness or drowsiness. Driving or operating machinery should be avoided until an individual knows how the medicine affects them, due to the risk of impaired judgment or motor skills.


Q: How does Tepilta's purpose relate to inflammation or immunity?

The primary mechanisms of action focus on achieving surface anesthesia and neutralizing acid in the stomach. While the product is used to relieve pain from irritated or inflamed linings, its action is topical and does not involve a systemic anti-inflammatory or immune-modulating effect.


Q: What is the function of the inactive ingredients in Tepilta?

The inactive ingredients (excipients) in the oral suspension are included to ensure the product remains stable and safe for use over time. These components often act as preservatives, thickeners, or sweeteners to help the medicine effectively coat the esophagus and stomach lining.

How should Tepilta be stored and disposed of?

Storage and Disposal Requirements

Official labeling for Tepilta (Oxetacaine, Aluminum Hydroxide, and Magnesium Hydroxide Oral Suspension) outlines specific requirements for storage, stability, and disposal to maintain product integrity and safety.

Storage Scope Official Regulatory Requirement
Temperature Range Store at controlled room temperature, specifically between 20 C and 25 C (68 F and 77 F); Do not freeze
In-Use Stability Once opened, the product should be used within 4 weeks, or by the expiry date, whichever is earlier.
Handling Rules Shake well before using and keep the bottle tightly closed.
Child Protection Keep the medicine out of the sight and reach of children.
Disposal Instructions Unused or expired product should be returned to a pharmacy for disposal or handled in accordance with local regulations.

The regulatory profile mandates storing the suspension in its original, tightly closed container and protecting it from freezing, excess heat, and moisture. The 4-week post-opening use limit is defined to ensure stability. Disposal must follow officially established pharmaceutical waste protocols.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Tepilta found in:

A-Z Index: